Cargando…

Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study

OBJECTIVES: To study the responsiveness of a combined power Doppler and greyscale ultrasound (PDUS) score for assessing synovitis in biologic-naïve patients with rheumatoid arthritis (RA) starting abatacept plus methotrexate (MTX). METHODS: In this open-label, multicentre, single-arm study, patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	D'Agostino, Maria-Antonietta, Wakefield, Richard J, Berner-Hammer, Hilde, Vittecoq, Olivier, Filippou, Georgios, Balint, Peter, Möller, Ingrid, Iagnocco, Annamaria, Naredo, Esperanza, Østergaard, Mikkel, Boers, Maarten, Gaillez, Corine, Van Holder, Karina, Le Bars, Manuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036216/ https://www.ncbi.nlm.nih.gov/pubmed/26590174 http://dx.doi.org/10.1136/annrheumdis-2015-207709

Ejemplares similares

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study
por: D'Agostino, Maria-Antonietta, et al.
Publicado: (2016)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
por: Smolen, Josef S., et al.
Publicado: (2015)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis
por: Derambure, Céline, et al.
Publicado: (2020)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019)

Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE
por: D’Agostino, Maria Antonietta, et al.
Publicado: (2021)

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
por: D’Agostino, Maria-Antonietta, et al.
Publicado: (2017)

Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis
por: Derambure, C., et al.
Publicado: (2017)

Is synovial hypertrophy without Doppler activity sensitive to change? Post-hoc analysis from a rheumatoid arthritis ultrasound study
por: Terslev, Lene, et al.
Publicado: (2018)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
por: Hirabara, Shinya, et al.
Publicado: (2014)

OMERACT agreement and reliability study of ultrasonographic elementary lesions in osteoarthritis of the foot
por: Zabotti, Alen, et al.
Publicado: (2019)

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
por: McInnes, Iain B, et al.
Publicado: (2019)

Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR
por: Mandl, Peter, et al.
Publicado: (2019)

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
por: Kremer, Joel M, et al.
Publicado: (2011)

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
por: Conaghan, Philip G, et al.
Publicado: (2011)

Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry
por: Nourisson, Cynthia, et al.
Publicado: (2017)

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system
por: Terslev, Lene, et al.
Publicado: (2017)

The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab
por: Provan, Sella Aarrestad, et al.
Publicado: (2015)

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
por: Schiff, M, et al.
Publicado: (2008)

Three-dimensional Doppler ultrasound findings in healthy wrist and finger tendon sheaths - can feeding vessels lead to misinterpretation in Doppler-detected tenosynovitis?
por: Ammitzbøll-Danielsen, Mads, et al.
Publicado: (2016)

Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce—Part 1: definition and development of a standardised, consensus-based scoring system
por: D’Agostino, Maria-Antonietta, et al.
Publicado: (2017)

Ultrasound in the evaluation of enthesitis: status and perspectives
por: Gandjbakhch, Frédérique, et al.
Publicado: (2011)

Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off
por: Yazici, Yusuf
Publicado: (2012)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
por: Yokoyama-Kokuryo, Waka, et al.
Publicado: (2020)

Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis
por: Hammer, Hilde Berner, et al.
Publicado: (2011)

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs
por: Takeuchi, Tsutomu, et al.
Publicado: (2014)

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

Case Report: Refractory Autoimmune Gastritis Responsive to Abatacept in LRBA Deficiency
por: Boz, Valentina, et al.
Publicado: (2021)

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
por: Bergman, Martin, et al.
Publicado: (2022)

Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials
por: Simon, Teresa A., et al.
Publicado: (2019)

Two Cases of Inadequate Response to Remimazolam
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
por: Alten, Rieke, et al.
Publicado: (2016)

Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
por: Bergman, Martin, et al.
Publicado: (2022)

Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis
por: Østergaard, Mikkel, et al.
Publicado: (2022)

Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate
por: Lee, Won-Seok, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mh32nuj3i46o3uidl6a9db4ksf